MedRhythms, Roux Institute Partner in the Fields of Neuroscience, Artificial Intelligence
The Roux Institute, based in Portland, Maine, was established in January 2020 through a $100 million investment by David and Barbara Roux. In remarks at the opening of the Institute, Roux stated that “we live in an innovation economy, but we are not participating fully,” and that the Institute will produce “the next generation of talent to participate in the innovation economy and attract and grow dynamic companies in the state.” Illustrating this unmet demand, Georgetown University released a 2019 report which suggested there were millions of artificial intelligence jobs, but only 300,000 people with the expertise necessary to fulfill these positions.
As a premier digital therapeutics company, MedRhythms recognizes the establishment of a graduate school specializing in artificial intelligence and the life sciences to be perfectly aligned with the company’s focus areas. Looking toward 2021, MedRhythms is eager to begin working with Roux Institute graduate students through co-op placements and joint research projects that leverage Northeastern University’s world-class, cutting-edge research capabilities.
“It is essential for a fast-growing company to recruit and retain talented engineers, researchers and scientists, but this has historically been challenging in Maine,” said Brian Bousquet-Smith, MedRhythms’ head of engineering. “The Roux Institute will reinvigorate the state’s talent pool and catalyze growth in the local tech economy. We are especially thrilled that this partnership will allow MedRhythms to expand its recruitment program to involve a top research institution, while at the same time providing their students with meaningful and innovative work experiences.”
By pursuing a co-op opportunity in Portland, students are able to collaborate with a tight knit community of leaders and innovators while enjoying an appealing cultural scene and access to an outdoors lifestyle. MedRhythms is a pioneer within an expanding group of high-growth organizations aligning themselves with the Roux Institute, including IDEXX, MaineHealth, L.L. Bean, and The Jackson Laboratory.
“MedRhythms is an exciting, Maine-based startup that is deeply engaged in translational research at the interface of technology and medicine - this is right in the sweet spot of the research and learning focus we have established at the Roux Institute,” said Mike Pollastri, senior vice provost and academic chair for the Roux Institute. “We’ve been engaged with MedRhythms since the earliest days, and their needs and interests for talent and innovation helped us sharpen our vision; and our faculty are incredibly enthusiastic about the collaborative research opportunities around their core technology approaches.”
MedRhythms, a privately held company headquartered in Portland, ME, is a digital therapeutics company that uses sensors, music, and software to build evidence-based, neurologic interventions to measure and improve walking. MedRhythms is dedicated to developing direct stimulation digital therapeutics, meaning that each therapeutic provides, via prescription music, direct stimulation to enable the mechanism of action in each relevant population. The company has an active pipeline of prescription digital therapeutics targeting rehabilitation and prevention in areas of neurologic injury and disease. The MedRhythms team has extensive experience in rehabilitation techniques utilizing music. The company has roots as a therapy services company that launched out of Spaulding Rehabilitation Hospital, which the U.S. News & World Report named the No. 2 ranked rehabilitation hospital in the country. To learn more, visit: www.medrhythms.com.
About The Roux Institute
The Roux Institute at Northeastern University is designed to educate generations of talent for the digital and life sciences sectors and drive sustained economic growth in Portland, the state of Maine, and northern New England. Its graduate degree and certificate programs will focus on the practical application of artificial intelligence and machine learning in the digital and life sciences to prepare people for high-demand jobs and drive research that meets industry needs.
THIS MANAGEMENT COMMENTARY CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO THE COMPANY THAT ARE BASED ON INFORMATION AVAILABLE TO US AS OF THE DATE HEREOF. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS ABOUT THE COMPANY'S BELIEFS, DESIGNS, ANTICIPATION, AIMS, GOALS, EXPECTATIONS AND POTENTIAL RESULTS ARE FORWARD-LOOKING STATEMENTS. IN ADDITION, THE WORDS "WILL," "MAY," "BELIEVE," "ANTICIPATE," "INTEND," "ESTIMATE," "EXPECT," "PROJECT," "PLAN," "SHOULD," "COULD," AND SIMILAR EXPRESSIONS, AND THEIR VARIATIONS AND NEGATIVES, AS THEY RELATE TO THE COMPANY OR THE FUTURE PERFORMANCE OF THE COMPANY, ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. SUCH FORWARD LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES, ASSUMPTIONS AND OTHER IMPORTANT FACTORS THAT COULD CAUSE THE COMPANY'S ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH FORWARD LOOKING STATEMENTS. THIS MANAGEMENT COMMENTARY SPEAKS ONLY AS OF THE DATE HEREOF AND THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO UPDATE THIS COMMENTARY IN THE FUTURE.